GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Samchundang Pharm Co Ltd (XKRX:000250) » Definitions » Debt-to-Revenue

Samchundang Pharm Co (XKRX:000250) Debt-to-Revenue : 0.26 (As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Samchundang Pharm Co Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Samchundang Pharm Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩33,696 Mil. Samchundang Pharm Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩19,929 Mil. Samchundang Pharm Co's annualized Revenue for the quarter that ended in Dec. 2023 was ₩209,966 Mil. Samchundang Pharm Co's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.26.


Samchundang Pharm Co Debt-to-Revenue Historical Data

The historical data trend for Samchundang Pharm Co's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Samchundang Pharm Co Debt-to-Revenue Chart

Samchundang Pharm Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.13 0.16 0.31 0.43 0.28

Samchundang Pharm Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.43 0.48 0.45 0.37 0.26

Competitive Comparison of Samchundang Pharm Co's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Samchundang Pharm Co's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Samchundang Pharm Co's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Samchundang Pharm Co's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Samchundang Pharm Co's Debt-to-Revenue falls into.



Samchundang Pharm Co Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Samchundang Pharm Co's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(33696.014 + 19928.919) / 192668.516
=0.28

Samchundang Pharm Co's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(33696.014 + 19928.919) / 209965.552
=0.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2023) Revenue data.


Samchundang Pharm Co Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Samchundang Pharm Co's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Samchundang Pharm Co (XKRX:000250) Business Description

Traded in Other Exchanges
N/A
Address
1606-1 SeoCho-Dong, SeoCho-Gu, Seoul, KOR, 137-877
Samchundang Pharm Co Ltd is engaged in manufacturing, distributing, importing, and exporting pharmaceuticals in South Korea. The company offers ophthalmology, cardiovascular, endocrinology, antibacterial, anti-fungal, antiviral, respiratory, anti-inflammatory, antihistamine, and musculoskeletal products, as well as gastro intestines and vitamins.

Samchundang Pharm Co (XKRX:000250) Headlines

No Headlines